2,6-dichloro-9-(2-C-methyl-2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-9H-purine | 205171-10-4

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 2,6-dichloro-9-(2-C-methyl-2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-9H-purine
• 英文别名: 2,6-dichloro-9H-(2-C-methyl-2,3,5-O-benzoyl-β-D-ribofuranosyl)purine；2,6-Dichloro-9-(2-c-methyl-2,3,5-tri-O-benzoyl-beta-D-ribofuranosyl)purine；[(2R,3R,4R,5R)-3,4-dibenzoyloxy-5-(2,6-dichloropurin-9-yl)-4-methyloxolan-2-yl]methyl benzoate
• CAS: 205171-10-4
• 化学式: C₃₂H₂₄Cl₂N₄O₇
• 分子量: 647.471
• InChiKey: XTCBOJNEMVXZEK-ZLZVUVTQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  45
• 可旋转键数：
  11
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  132
• 氢给体数：
  0
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  2,6-dichloro-9-(2-C-methyl-2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-9H-purine 在 TEA 、 氨 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 2.0h， 生成 (2R,3R,4R,5R)-2-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)-3-methyloxolane-3,4-diol
  参考文献：
  名称：

  Synthesis, Biological Evaluation, and Molecular Modeling of Ribose-Modified Adenosine Analogues as Adenosine Receptor Agonists

  摘要：

  A number of 3'-C-methyl analogues of selective adenosine receptor agonists such as CPA, CHA, CCPA, 2'-Me-CCPA, NECA, and IB-MECA was synthesized to further investigate the subdomain of the receptor that binds the ribose moiety of the ligands. Affinity data at A(1), A(2A), and A(3) receptors in bovine brain membranes showed that the X-C-modification in adenosine resulted in a decrease of the affinity at all three receptor subtypes. When this modification was combined with N-6-substitution with groups that induce high potency and selectivity at A(1) receptor, the affinity and selectivity were increased. However, all X-C-methyl derivatives proved to be very less active than the corresponding 2'-C-methyl analogues. The most active compound was found to be 3'-Me-CPA which displayed a K-i value of 0.35 muM at A(1) receptor and a selectivity for A(1) vs A(2A) and A(3) receptors higher than 28-fold. 2'-Me-CCPA was confirmed to be the most selective, high affinity agonist so far known also at human A(1) receptor with a K-i value of 3.3 nM and 2903- and 341-fold selective vs human A(2A) and A(3) receptors, respectively. In functional assay, 3'-Me-CPA, 3'-Me-CCPA, and 2-Cl-3'-Me-IB-MECA inhibited forskolin-stimulated adenylyl cyclase activity with IC50 values ranging from 0.3 to 4.9 muM, acting as full agonists. A rhodopsin-based model of the bovine A(1)AR was built to rationalize the higher affinity and selectivity of 2'-C-methyl derivatives of N-6-substituted-adenosine compared to that of 3'-C-methyl analogues. In the docking exploration, it was found that 2'-Me-CCPA was able to form a number of interactions with several polar residues in the transmembrane helices TM-3, TM-6, and TM-7 of bA(1)AR which were not preserved in the molecular dynamics simulation of 3'-Me-CCPA/bA(1)AR complex.

  DOI：

  10.1021/jm049408n
• 作为产物：
  描述：

  2-C-甲基-D-核糖酸-1,4-内酯 在 三氟甲磺酸三甲基硅酯 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 lithium tri-t-butoxyaluminum hydride 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙腈 为溶剂， 反应 8.25h， 生成 2,6-dichloro-9-(2-C-methyl-2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-9H-purine
  参考文献：
  名称：

  Synthesis and Evaluation of 2,6-Modified Purine 2′-C-Methyl Ribonucleosides as Inhibitors of HCV Replication

  摘要：

  A variety of 2,6-modified purine 2'-C-methylribonucleosides and their phosphoramidate prodrugs were synthesized and evaluated for inhibition of HCV RNA replication in Huh-7 cells and for cytotoxicity in various cell lines. Cellular pharmacology and HCV polymerase incorporation studies on the most potent and selective compound are reported.

  DOI：

  10.1021/acsmedchemlett.5b00402

文献信息

• [EN] INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE<br/>[FR] INHIBITEURS DE L'ADÉNOSINE 5'-NUCLÉOTIDASE
  申请人：ARCUS BIOSCIENCES INC

  公开号：WO2018067424A1

  公开（公告）日：2018-04-12

  Compounds that modulate the conversion of AMP to adenosine by 5'- nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5'-nueleotidase, ecto is also provided.

  描述了调节5'-核苷酸酶、外泌体将AMP转化为腺苷的化合物，以及包含这些化合物的组合物和合成这些化合物的方法。还提供了这些化合物和组合物用于治疗和/或预防由5'-核苷酸酶、外泌体介导的一组多种疾病、紊乱和状况，包括癌症和免疫相关紊乱的使用。
• <i>N</i>⁶-Cycloalkyl- and <i>N</i>⁶-Bicycloalkyl-<i>C</i>5′(<i>C</i>2′)-modified Adenosine Derivatives as High-Affinity and Selective Agonists at the Human A₁ Adenosine Receptor with Antinociceptive Effects in Mice
  作者：Palmarisa Franchetti、Loredana Cappellacci、Patrizia Vita、Riccardo Petrelli、Antonio Lavecchia、Sonja Kachler、Karl-Norbert Klotz、Ida Marabese、Livio Luongo、Sabatino Maione、Mario Grifantini

  DOI：10.1021/jm801456g

  日期：2009.4.23

  N6-(endo-norborn-2-yl)adenosine derivatives, 5′-chloro-5′-deoxy-CPA (1) and 5′-chloro-5′-deoxy-(±)-ENBA (3) displayed the highest affinity in the subnanomolar range and relevant selectivity for hA1 vs the other human receptor subtypes. The higher affinity and selectivity of 5′-chloro-5′-deoxyribonucleoside derivatives 1 and 3 for hA1 AR vs hA3 AR compared to that of the parent 5′-hydroxy compounds CPA and (±)-ENBA

  为了进一步研究新型有效和选择性的人A 1腺苷受体激动剂，我们合成了一系列5'-氯-5'-脱氧-和5'-（2-氟苯硫基）-5'-脱氧-N 6-环烷基（双环烷基）-取代的腺苷和2'- C-甲基腺苷衍生物。评价这些化合物对人A 1，A 2A，A 2B和A 3腺苷受体的亲和力和功效。在一系列N 6-环戊基和N 6-（内降冰片-2-基）腺苷衍生物中，5'-chloro-5'-deoxy-CPA（1）和5'-chloro-5'- deoxy-CPA（1） （±）-ENBA（3）显示出在亚纳摩尔范围内的最高亲和力和对hA 1的选择性相对于其他人类受体亚型。5'-chloro-5'-脱氧核糖核苷衍生物1和3对hA 1 AR与hA 3 AR的亲和力和选择性与母体5'-羟基化合物CPA和（±）-ENBA的亲和力和选择性通过分子合理化建模分析。5'-Chloro-5'-deoxy-（±）-ENBA在福尔马林试验
• Synthesis of purine modified 2′-C-methyl nucleosides as potential anti-HCV agents
  作者：Hong-wang Zhang、Longhu Zhou、Steven J. Coats、Tamara R. McBrayer、Phillip M. Tharnish、Lavanya Bondada、Mervi Detorio、Sarah A. Amichai、Melissa D. Johns、Tony Whitaker、Raymond F. Schinazi

  DOI：10.1016/j.bmcl.2011.09.034

  日期：2011.11

  Based on the anti-hepatitis C activity of 2′-C-methyl-adenosine and 2′-C-methyl-guanosine, a series of new modified purine 2′-C-methyl nucleosides was prepared as potential anti-hepatitis C virus agents. Herein, we report the synthesis of both 6-modified and 2-modified purine 2′-C-methyl-nucleosides along with their anti-HCV replication activity and cytotoxicity in different cells.

  基于2' - C-甲基-腺苷和2' - C-甲基-鸟苷的抗丙型肝炎活性，制备了一系列新型修饰嘌呤2'- C-甲基核苷作为潜在的抗丙型肝炎病毒药物. 在此，我们报告了 6-修饰和 2-修饰的嘌呤 2' - C-甲基-核苷的合成以及它们在不同细胞中的抗 HCV 复制活性和细胞毒性。
• Ectonucleotidase inhibitors and methods of use thereof
  申请人：Calithera Biosciences, Inc.

  公开号：US10570167B2

  公开（公告）日：2020-02-25

  The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.

  本发明涉及新型杂环化合物及其药物制剂。本发明还涉及使用本发明的新型杂环化合物治疗或预防癌症的方法。
• Modulators of 5′-nucleotidase, ecto and the use thereof
  申请人：ARCUS BIOSCIENCES, INC.

  公开号：US10981944B2

  公开（公告）日：2021-04-20

  Compounds that modulate the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5′-nucleotidase, ecto is also provided.

  本文描述了调节 5′-核苷酸酶将 AMP 转化为腺苷的化合物，以及含有这些化合物的组合物和合成这些化合物的方法。还提供了这些化合物和组合物用于治疗和/或预防由 5′-核苷酸酶外切酶介导的各种疾病、失调和病症，包括癌症和免疫相关失调。